Inspire Pharmaceuticals, Inc. And FAES Farma Announce Licensing Agreement For New Oral Antihistamine To Target Allergy Market In United States And Canada; Up to $89 Million
DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) and FAES Farma, S.A. (IBEX: FAE) announced today the signing of a licensing agreement for the U.S. and Canadian development and commercialization of bilastine, a Phase 3 oral antihistamine compound for the treatment or prevention of allergic rhinitis, a condition affecting approximately 40 million people in the United States.